Moran Wealth Management LLC Buys Shares of 10,075 Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Moran Wealth Management LLC purchased a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) in the fourth quarter, Holdings Channel.com reports. The fund purchased 10,075 shares of the biopharmaceutical company’s stock, valued at approximately $210,000.

Several other institutional investors have also recently made changes to their positions in CPRX. AlphaQuest LLC grew its position in Catalyst Pharmaceuticals by 17.6% in the fourth quarter. AlphaQuest LLC now owns 43,916 shares of the biopharmaceutical company’s stock worth $917,000 after acquiring an additional 6,582 shares during the period. Amundi lifted its stake in shares of Catalyst Pharmaceuticals by 188.2% in the 4th quarter. Amundi now owns 56,609 shares of the biopharmaceutical company’s stock valued at $1,291,000 after purchasing an additional 36,968 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of Catalyst Pharmaceuticals during the 4th quarter worth $6,887,000. Proficio Capital Partners LLC purchased a new stake in Catalyst Pharmaceuticals in the 4th quarter valued at about $339,000. Finally, Victory Capital Management Inc. raised its holdings in Catalyst Pharmaceuticals by 1.6% in the 4th quarter. Victory Capital Management Inc. now owns 296,080 shares of the biopharmaceutical company’s stock valued at $6,179,000 after buying an additional 4,575 shares during the period. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on CPRX. StockNews.com raised shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 28th. Robert W. Baird lifted their target price on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an “outperform” rating in a report on Monday, March 3rd. Baird R W upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Monday, February 3rd. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. Finally, Bank of America reiterated a “buy” rating and issued a $30.00 price objective on shares of Catalyst Pharmaceuticals in a report on Thursday, January 9th. Eight research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $32.50.

Insider Transactions at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Gary Ingenito sold 44,904 shares of the business’s stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total transaction of $991,929.36. Following the completion of the transaction, the insider now owns 68,873 shares in the company, valued at $1,521,404.57. The trade was a 39.47 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Brian Elsbernd sold 62,975 shares of the firm’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the completion of the sale, the insider now owns 188,564 shares in the company, valued at $4,333,200.72. The trade was a 25.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 11.00% of the company’s stock.

Catalyst Pharmaceuticals Price Performance

CPRX opened at $21.20 on Thursday. The stock has a market capitalization of $2.57 billion, a price-to-earnings ratio of 17.97, a PEG ratio of 3.31 and a beta of 0.84. The business has a fifty day moving average price of $22.27 and a 200 day moving average price of $21.52. Catalyst Pharmaceuticals, Inc. has a 12 month low of $14.47 and a 12 month high of $24.64.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.